The FGFR3 oncogenic pathway is associated with a non-T-cell-inflamed cancer phenotype, characterized by reduced CD8+ T cells, chemokines, and interferons, resulting in resistance to immune checkpoint inhibitors [20]. This evidence concerns the gene CD8A and cancer.